Source: Virtual Congress 2021 – Difficult decisions on expected outcomes: availability of hospital resources and improvement of treatment adherence



Rating:

Share or cite this content

Citations should be made in the following way:
V. Paly (Philadelphia, United States of America), L. Vallejo-Aparicio (Madrid, Spain), A. Gabrio (London, United Kingdom), G. Baio (London, United Kingdom), A. Martin (Uxbridge, United Kingdom), A. Ismaila (Collegeville, United States of America). IMPACT: Healthcare resource use data and associated costs for single-inhaler triple therapy versus dual therapies in Spain. 4283

Member's Comments

No comment yet.

Related content which might interest you: Impact of once-daily single inhaler triple therapy on healthcare resource utilization and associated costs in COPD patients in Spain Source: International Congress 2018 – COPD, asthma and tuberculosis: benefits related to therapy costs Year: 2018 Is single-inhaler triple therapy for COPD cost-effective in the UK? The IMPACT trial Source: ERJ Open Res, 8 (1) 00333-2021; 10.1183/23120541.00333-2021 Year: 2022 Late Breaking Abstract - IMPACT study — single inhaler triple therapy (FF/UMEC/VI) versus FF/VI and UMEC/VI in patients with COPD: healthcare resource utilization and costs — UK Source: International Congress 2018 – COPD: from LABA/ICS to LABA/LAMA/ICS Year: 2018 Single inhaler triple therapy in patients with advanced COPD: healthcare resource utilisation and cost data from the FULFIL study Source: International Congress 2017 – Does economisation of medicine transfer into benefits for patients? Year: 2017 Healthcare costs associated with short-acting ß2-agonist use in asthma: an observational UK study from the SABINA global programme Source: Virtual Congress 2021 – Advances in asthma treatment Year: 2021 Cost consequences of tiotropium plus existing therapy versus existing therapy alone following one year of treatment in patients with COPD Source: Eur Respir J 2001; 18: Suppl. 33, 5s Year: 2001 Economic evaluation of the impact of exacerbation frequency in COPD patients treated with single-inhaler triple therapy in Spain: The IMPACT trial Source: Virtual Congress 2020 – Pharmacological management of COPD Year: 2020 Cost impact of time to initiation of triple therapy in COPD patients in Japan: A retrospective analysis of healthcare claims data Source: International Congress 2017 – Does economisation of medicine transfer into benefits for patients? Year: 2017 Cost-effectiveness analysis of a single-inhaler triple therapy for COPD in the UK Source: ERJ Open Res, 7 (1) 00480-2020; 10.1183/23120541.00480-2020 Year: 2021 Cost-effectiveness of single- vs multiple-inhaler triple therapy in a UK COPD population: INTREPID trial Source: Virtual Congress 2021 – Highlights for primary care in 2021 Year: 2021 Are patients with COPD more adherent to single-inhaler compared with multiple-inhaler triple therapy in a real-world UK primary care treated population? Source: Virtual Congress 2021 – COPD pharmacology: from basic science to real-world data Year: 2021 Real-world effectiveness and cost-effectiveness of asthma step-up options: A UK comparison of extrafine hydrofluoroalkane-beclometasone and combination therapy Source: Annual Congress 2013 –Treatment and management of asthma in primary care Year: 2013 Impact of reimbursement changes for fixed ICS/LABA combination treatment in Iceland Source: Annual Congress 2012 - Healthcare utilisation and treatment of asthma and COPD Year: 2012 Cost-effectiveness of fixed-dose combinations therapies for COPD in Spain Source: International Congress 2017 – Does economisation of medicine transfer into benefits for patients? Year: 2017 Resource utilization and economic impact of switching uncontrolled asthma and exacerbating COPD patients on monotherapy to fixed dose combination treatment in Germany Source: Annual Congress 2012 - Looking at the cost effectiveness of asthma and COPD treatment by novel drugs and improved management Year: 2012 Comparison of dual vs triple therapies in patients hospitalized for COPD in France: a claims data study Source: International Congress 2018 – COPD management Year: 2018 Clinical and economic impact of an improvement in adherence based on specific attributes of single-inhaler triple therapies in COPD patients Source: International Congress 2019 – Inhalers: adherence and preference Year: 2019 LAMA/LABA vs. LABA/ICS and triple therapy – is ICS in again? Source: International Congress 2018 – Preventing asthma and COPD exacerbations by increasing the inhaled glucocorticoid dose Year: 2018 Late Breaking Abstract - Cost effectiveness of as-needed budesonide/formoterol vs low-dose ICS maintenance therapy in mild asthma patients: A UK perspective Source: International Congress 2019 – How to guide patients to reach a balance between costs and personal needs: quality indicators of effectiveness Year: 2019 Cost-effectiveness of treating MDR-TB by adding delamanid to background regimens in Germany Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015